{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T05:08:23Z","timestamp":1782796103107,"version":"3.54.5"},"reference-count":86,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain and Development"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.braindev.2012.03.015","type":"journal-article","created":{"date-parts":[[2012,4,25]],"date-time":"2012-04-25T14:45:00Z","timestamp":1335365100000},"page":"119-127","source":"Crossref","is-referenced-by-count":39,"title":["Pharmacotherapy of autism spectrum disorders"],"prefix":"10.1016","volume":"35","author":[{"given":"Arianna","family":"Benvenuto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Battan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Porfirio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Curatolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.braindev.2012.03.015_b0435","unstructured":"Autism and Developmental Disabilities Monitoring Network Surveillance Year 2006 Principal Investigators, Centers for Disease Control and Prevention (CDC). Prevalence of autism spectrum disorders \u2013 Autism and Developmental Disabilities Monitoring Network, United States, MMWR Surveill Summ 2009; 58:1\u201320."},{"key":"10.1016\/j.braindev.2012.03.015_b0010","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s12519-009-0033-2","article-title":"Syndromic autism: causes and pathogenetic pathways","volume":"5","author":"Benvenuto","year":"2009","journal-title":"World J Pediatr"},{"key":"10.1016\/j.braindev.2012.03.015_b0015","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10571-009-9453-8","article-title":"Understanding and determining the etiology of autism","volume":"30","author":"Currenti","year":"2010","journal-title":"Cell Mol Neurobiol"},{"key":"10.1016\/j.braindev.2012.03.015_b0020","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s10803-006-0340-6","article-title":"Predictors of optimal outcome in Toddlers diagnosed with autism spectrum disorders","volume":"37","author":"Sutera","year":"2007","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.braindev.2012.03.015_b0025","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3928\/00904481-20090301-01","article-title":"How can early, intensive training help a genetic disorder?","volume":"38","author":"Altemeier","year":"2009","journal-title":"Pediatr Ann"},{"key":"10.1016\/j.braindev.2012.03.015_b0030","article-title":"An Italian prospective study on autism treatment: the earlier, the better?","author":"Vivanti","year":"2011","journal-title":"Autism"},{"key":"10.1016\/j.braindev.2012.03.015_b0035","first-page":"213","article-title":"Novel and emerging treatments for autism spectrum disorders: a systematic review","volume":"21","author":"Rossignol","year":"2009","journal-title":"Ann Clin Psychiatry"},{"key":"10.1016\/j.braindev.2012.03.015_b0040","first-page":"155","article-title":"Pharmacologic treatment of autism","volume":"19","author":"Palermo","year":"2004","journal-title":"J Child Neurol"},{"key":"10.1016\/j.braindev.2012.03.015_b0045","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.pedhc.2008.12.001","article-title":"Pharmacologic treatment for the core deficits and associated symptoms of autism in children","volume":"23","author":"West","year":"2009","journal-title":"J Pediatr Health Care"},{"key":"10.1016\/j.braindev.2012.03.015_b0050","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1007\/s10803-010-1140-6","article-title":"Assessment of health-related quality of life among primary caregivers of children with autism spectrum disorders","volume":"41","author":"Khanna","year":"2011","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.braindev.2012.03.015_b0055","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s10803-009-0921-2","article-title":"Health-related quality of life in children with autism spectrum disorders: results from the autism treatment network","volume":"40","author":"Kuhlthau","year":"2010","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.braindev.2012.03.015_b0060","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/j.1365-2788.2008.01065.x","article-title":"Prevalence and risk factors of maladaptive behaviour in young children with autistic disorder","volume":"52","author":"Hartley","year":"2008","journal-title":"J Intellect Disabil Res"},{"key":"10.1016\/j.braindev.2012.03.015_b0065","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1089\/cap.2009.0048","article-title":"Effectiveness of medication combined with intensive behavioral intervention for reducing aggression in youth with autism spectrum disorder","volume":"20","author":"Frazier","year":"2010","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.braindev.2012.03.015_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.annepidem.2011.10.007","article-title":"High prescription drug use and associated costs among medicaid-eligible children with autism spectrum disorders identified by a population-based surveillance network","volume":"22","author":"Logan","year":"2012","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.braindev.2012.03.015_b0075","doi-asserted-by":"crossref","first-page":"e1312","DOI":"10.1542\/peds.2011-0427","article-title":"A systematic review of medical treatments for children with autism spectrum disorders","volume":"127","author":"McPheeters","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.braindev.2012.03.015_b0080","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ridd.2011.10.008","article-title":"Concurrent medical conditions and health care use and needs among children with learning and behavioral developmental disabilities, National Health Interview Survey, 2006\u20132010","volume":"33","author":"Schieve","year":"2011","journal-title":"Res Dev Disabil"},{"key":"10.1016\/j.braindev.2012.03.015_b0085","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2165\/11316140-000000000-00000","article-title":"Epidemiology and management of insomnia in children with autistic spectrum disorders","volume":"12","author":"Miano","year":"2010","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.braindev.2012.03.015_b0090","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1469-8749.2011.03980.x","article-title":"Melatonin in autism spectrum disorders: a systematic review and meta-analysis","volume":"53","author":"Rossignol","year":"2011","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.braindev.2012.03.015_b0095","article-title":"Melatonin for sleep in children with autism: a controlled trial examining dose, tolerability, and outcomes","author":"Malow","year":"2011","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.braindev.2012.03.015_b0100","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1471-2431-11-37","article-title":"Traditional and non-traditional treatments for autism spectrum disorder with seizures: an on-line survey","volume":"11","author":"Frye","year":"2011","journal-title":"BMC Pediatr"},{"key":"10.1016\/j.braindev.2012.03.015_b0105","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1007\/s10803-010-1118-4","article-title":"Aggression in children and adolescents with ASD: prevalence and risk factors","volume":"41","author":"Kanne","year":"2011","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.braindev.2012.03.015_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00787-007-0620-5","article-title":"Risperidone versus haloperidol in children and adolescents with AD: a randomized, controlled, double-blind trial","volume":"17","author":"Miral","year":"2008","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.1016\/j.braindev.2012.03.015_b0115","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1176\/appi.ajp.162.6.1142","article-title":"Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology","volume":"162","author":"McDougle","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.braindev.2012.03.015_b0120","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1177\/08830738060210060801","article-title":"Risperidone in children with autism: randomized, placebo-controlled, double-blind study","volume":"21","author":"Nagaraj","year":"2006","journal-title":"J Child Neurol"},{"key":"10.1016\/j.braindev.2012.03.015_b0125","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10803-006-0234-7","article-title":"Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial","volume":"37","author":"Pandina","year":"2007","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.braindev.2012.03.015_b0130","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1089\/cap.2005.15.869","article-title":"Acute and long-term safety and tolerability of risperidone in children with autism","volume":"15","author":"Aman","year":"2005","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.braindev.2012.03.015_b0135","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.biopsych.2006.02.032","article-title":"Effects of short- and long-term risperidone treatment on prolactin levels in children with autism","volume":"61","author":"Anderson","year":"2007","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.braindev.2012.03.015_b0140","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/CHI.0b013e3181b76658","article-title":"A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder","volume":"48","author":"Marcus","year":"2009","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.braindev.2012.03.015_b0145","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1542\/peds.2008-3782","article-title":"Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder","volume":"124","author":"Owen","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.braindev.2012.03.015_b0150","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1089\/cap.2009.0121","article-title":"Aripiprazole in the treatment of irritability in pediatric patients (aged 6\u201317 years) with autistic disorder: results from a 52-week, open-label study","volume":"21","author":"Marcus","year":"2011","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.braindev.2012.03.015_b0155","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/JCP.0b013e318218f4a1","article-title":"Retrospective review of clozapine in the treatment of patients with autism spectrum disorder and severe disruptive behaviors","volume":"31","author":"Beherec","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.braindev.2012.03.015_b0160","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1089\/cap.2006.16.541","article-title":"A doubl blind placebo-controlled pilot study of olanzapine in childhood\/adolescent pervasive developmental disorder","volume":"16","author":"Hollander","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.braindev.2012.03.015_b0165","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s11940-009-0043-3","article-title":"Pharmacologic treatment of impulsive aggression with antiepileptic drugs","volume":"11","author":"Stanford","year":"2009","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.braindev.2012.03.015_b0170","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/npp.2009.202","article-title":"Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders","volume":"35","author":"Hollander","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.braindev.2012.03.015_b0175","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1017\/S1461145705005791","article-title":"Divalproex sodium vs placebo in the treatment of repetitive behaviours in autism spectrum disorders","volume":"9","author":"Hollander","year":"2006","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.braindev.2012.03.015_b0180","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1089\/cap.2004.14.426","article-title":"A retrospective assessment of topiramate in children and adolescents with pervasive developmental disorders","volume":"14","author":"Hardan","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.braindev.2012.03.015_b0185","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.braindev.2006.05.004","article-title":"Topiramate in children with autistic spectrum disorders","volume":"28","author":"Mazzone","year":"2006","journal-title":"Brain Dev"},{"key":"10.1016\/j.braindev.2012.03.015_b0190","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.pnpbp.2010.07.005","article-title":"Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder","volume":"34","author":"Rezaei","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.braindev.2012.03.015_b0195","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/01.yic.0000224787.13782.0f","article-title":"Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study","volume":"21","author":"Wasserman","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.braindev.2012.03.015_b0200","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1023\/A:1010799115457","article-title":"Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial","volume":"31","author":"Belsito","year":"2001","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.braindev.2012.03.015_b0205","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00787-010-0092-x","article-title":"Shared heritability of attention-deficit\/hyperactivity disorder and autism spectrum disorder","volume":"19","author":"Rommelse","year":"2010","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.1016\/j.braindev.2012.03.015_b0210","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1089\/cap.2011.0057","article-title":"Prevalence and correlates of psychotropic medication use in adolescents with an autism spectrum disorder with and without caregiver-reported attention-deficit\/hyperactivity disorder","volume":"21","author":"Frazier","year":"2011","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.braindev.2012.03.015_b0215","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1440-1754.2007.00995.x","article-title":"Drug therapy for attention deficit\/ hyperactivity disorder-like symptoms in autistic disorder","volume":"43","author":"Hazell","year":"2007","journal-title":"J Paediatr Child Health"},{"key":"10.1016\/j.braindev.2012.03.015_b0220","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1089\/1044546041649011","article-title":"Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: an open-pilot study","volume":"14","author":"Di Martino","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.braindev.2012.03.015_b0225","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/archpsyc.62.11.1266","article-title":"Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity","volume":"62","author":"Research Units on Pediatric Psychopharmacology Autism Network","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.braindev.2012.03.015_b0230","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s10803-008-0636-9","article-title":"Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity","volume":"39","author":"Jahromi","year":"2009","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.braindev.2012.03.015_b0235","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.biopsych.2006.09.028","article-title":"Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures","volume":"61","author":"Posey","year":"2007","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.braindev.2012.03.015_b0240","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1089\/cap.2006.16.599","article-title":"Open-label atomoxetine for attention-deficit\/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders","volume":"16","author":"Posey","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.braindev.2012.03.015_b0245","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1177\/1087054710376907","article-title":"Efficacy of atomoxetine in children with severe autistic disorders and symptoms of ADHD: an open-label study","volume":"15","author":"Charnsil","year":"2011","journal-title":"J Atten Disord"},{"key":"10.1016\/j.braindev.2012.03.015_b0250","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1097\/01.chi.0000231976.28719.2a","article-title":"Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial","volume":"45","author":"Arnold","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.braindev.2012.03.015_b0255","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/j.1651-2227.2011.02263.x","article-title":"Response to atomoxetine in boys with high-functioning autism spectrum disorders and attention deficit\/hyperactivity disorder","volume":"100","author":"Zeiner","year":"2011","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.braindev.2012.03.015_b0260","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/cap.2006.16.589","article-title":"A prospective open trial of guanfacine in children with pervasive developmental disorders","volume":"16","author":"Scahill","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.braindev.2012.03.015_b0265","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/DBP.0b013e3181739b9d","article-title":"Guanfacine in children with autism and\/or intellectual disabilities","volume":"29","author":"Handen","year":"2008","journal-title":"J Dev Behav Pediatr"},{"key":"10.1016\/j.braindev.2012.03.015_b0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/cap.2009.0059","article-title":"Possible influence of variant of the P-glycoprotein gene (MDR1\/ABCB1) on clinical response to guanfacine in children with pervasive developmental disorders and hyperactivity","volume":"20","author":"McCracken","year":"2010","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.braindev.2012.03.015_b0275","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/00004714-199210000-00005","article-title":"Clonidine treatment of hyperactive and impulsive children with autistic disorder","volume":"12","author":"Jaselskis","year":"1992","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.braindev.2012.03.015_b0280","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.braindev.2007.12.007","article-title":"Use of clonidine in children with autism spectrum disorders","volume":"30","author":"Ming","year":"2008","journal-title":"Brain Dev"},{"key":"10.1016\/j.braindev.2012.03.015_b0285","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1744-6155.2009.00196.x","article-title":"Review of the evidence for treatment of children with autism with selective serotonin reuptake inhibitors","volume":"14","author":"West","year":"2009","journal-title":"J Spec Pediatr Nurs"},{"key":"10.1016\/j.braindev.2012.03.015_b0290","doi-asserted-by":"crossref","unstructured":"Williams K, Wheeler DM, Silove N, Hazell P. Selective serotonin reuptake inhibitors (SSRI) for autism spectrum disorders (ASD). Cochrane Database Syst Rev 2010; 8:CD004677.","DOI":"10.1002\/14651858.CD004677.pub2"},{"key":"10.1016\/j.braindev.2012.03.015_b0295","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/sj.npp.1300627","article-title":"A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism","volume":"30","author":"Hollander","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.braindev.2012.03.015_b0300","article-title":"A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders","author":"Hollander","year":"2011","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.braindev.2012.03.015_b0305","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1001\/archgenpsychiatry.2009.30","article-title":"Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism","volume":"66","author":"King","year":"2009","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.braindev.2012.03.015_b0310","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/01.chi.0000153229.80215.a0","article-title":"An open-label trial of escitalopram in pervasive developmental disorders","volume":"44","author":"Owley","year":"2005","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.braindev.2012.03.015_b0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/aur.109","article-title":"A pharmacogenetic study of escitalopram in autism spectrum disorders","volume":"3","author":"Owley","year":"2010","journal-title":"Autism Res"},{"key":"10.1016\/j.braindev.2012.03.015_b0320","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.braindev.2011.10.007","article-title":"Evaluation of the GABAergic nervous system in autistic brain: (123) I-iomazenil SPECT study","volume":"34","author":"Mori","year":"2012","journal-title":"Brain Dev"},{"key":"10.1016\/j.braindev.2012.03.015_b0325","article-title":"Glutamate mediated signaling in the pathophysiology of autism spectrum disorders","author":"Choudhury","year":"2011","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.braindev.2012.03.015_b0330","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00401-010-0655-4","article-title":"The neuropathology of autism: defects of neurogenesis and neuronal migration, and dysplastic changes","volume":"119","author":"Wegiel","year":"2010","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.braindev.2012.03.015_b0335","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/npp.2011.185","article-title":"Networking in autism: leveraging genetic, biomarker and model system findings in the search for new treatments","volume":"37","author":"Veenstra-Vanderweele","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.braindev.2012.03.015_b0340","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1517\/14728222.12.8.949","article-title":"Treatment of autism spectrum disorders: neurotransmitter signaling pathways involved in motivation and reward as therapeutic targets","volume":"12","author":"Walker","year":"2008","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.braindev.2012.03.015_b0345","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1089\/cap.2006.16.561","article-title":"Neuropsychological effects of risperidone in children with pervasive developmental disorders: a blinded discontinuation study","volume":"16","author":"Troost","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.braindev.2012.03.015_b0350","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ridd.2008.07.004","article-title":"Effects of risperidone on cognitive-motor performance and motor movements in chronically medicated children","volume":"30","author":"Aman","year":"2009","journal-title":"Res Dev Disabil"},{"key":"10.1016\/j.braindev.2012.03.015_b0355","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1089\/cap.2007.0133","article-title":"Cognitive effects of risperidone in children with autism and irritable behavior","volume":"18","author":"Aman","year":"2008","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.braindev.2012.03.015_b0360","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.pnpbp.2008.08.023","article-title":"Atypical neuroleptic risperidone modulates glial functions in C6 astroglial cells","volume":"33","author":"Quincozes-Santos","year":"2009","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.braindev.2012.03.015_b0365","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.expneurol.2011.03.015","article-title":"Pre- and post-treatments with escitalopram protect against experimental ischemic neuronal damage via regulation of BDNF expression and oxidative stress","volume":"229","author":"Lee","year":"2011","journal-title":"Exp Neurol"},{"key":"10.1016\/j.braindev.2012.03.015_b0370","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nature09582","article-title":"Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes","volume":"468","author":"Chao","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.braindev.2012.03.015_b0375","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.neulet.2006.11.062","article-title":"Major defects in neocortical GABAergic inhibitory circuits in mice lacking the fragile X mental retardation protein","volume":"412","author":"Selby","year":"2007","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.braindev.2012.03.015_b0380","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.molmed.2010.10.002","article-title":"Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders","volume":"17","author":"Ehninger","year":"2011","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.braindev.2012.03.015_b0385","doi-asserted-by":"crossref","first-page":"649325","DOI":"10.1155\/2011\/649325","article-title":"Genetics and function of neocortical GABAergic interneurons in neurodevelopmental disorders","volume":"2011","author":"Rossignol","year":"2011","journal-title":"Neural Plast"},{"key":"10.1016\/j.braindev.2012.03.015_b0390","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.braindev.2010.05.007","article-title":"Autism spectrum disorders and epilepsy: moving towards a comprehensive approach to treatment","volume":"32","author":"Tuchman","year":"2010","journal-title":"Brain Dev"},{"key":"10.1016\/j.braindev.2012.03.015_b0395","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.brainresbull.2011.08.001","article-title":"Complex effects of mGluR5 antagonism on sociability and stereotypic behaviors in mice. Possible implications for the pharmacotherapy of autism spectrum disorders","volume":"86","author":"Burket","year":"2011","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.braindev.2012.03.015_b0400","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1177\/0883073807302611","article-title":"Memantine in children with autistic spectrum sisorders","volume":"22","author":"Chez","year":"2007","journal-title":"J Child Neurol"},{"key":"10.1016\/j.braindev.2012.03.015_b0405","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/00004583-200106000-00010","article-title":"Double-blind, placebo-controlled study of amantidine hydrochloride in the treatment of children with autistic disorder","volume":"40","author":"King","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.braindev.2012.03.015_b0410","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.nurt.2010.05.006","article-title":"Autism and oxytocin: new developments in translational approaches to therapeutics","volume":"7","author":"Green","year":"2010","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.braindev.2012.03.015_b0415","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.biopsych.2009.09.020","article-title":"Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders","volume":"67","author":"Guastella","year":"2010","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.braindev.2012.03.015_b0420","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1097\/00004583-200312000-00005","article-title":"Evidence-based treatments in child and adolescent psychiatry: an inventory","volume":"42","author":"McClellan","year":"2003","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.braindev.2012.03.015_b0425","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/mp.2008.63","article-title":"Altered calcium homeostasis in autism-spectrum disorders: evidence from biochemical and genetic studies of the mitochondrial aspartate\/glutamate carrier AGC1","volume":"15","author":"Palmieri","year":"2010","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.braindev.2012.03.015_b0430","first-page":"83","article-title":"Can ziconotide as a N-type voltage-sensitive calcium channel blocker open a new mode for treatment of autism? A hypothesis","volume":"16","author":"Ghanizadeh","year":"2011","journal-title":"Neurosciences"}],"container-title":["Brain and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760412000927?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760412000927?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T22:32:40Z","timestamp":1713911560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0387760412000927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0387760412000927"],"URL":"https:\/\/doi.org\/10.1016\/j.braindev.2012.03.015","relation":{},"ISSN":["0387-7604"],"issn-type":[{"value":"0387-7604","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}